(January 17, 2012) -- An eight-day bench hearing held in Minneapolis, Minn., in December 2009, could have far-reaching legal implications for antitrust law, particularly regarding future pharmaceutical cases. It could set a precedent making it easier for judges to rule against government agencies on technical grounds of market definition, even when the victims are remarkably vulnerable—in this case, premature babies injured by what was alleged to be price-gouging by a monopolist....